Difamilast - Otsuka Pharmaceutical
Alternative Names: MM 36; MM-36-Medimetriks-Pharmaceuticals; Moizerto; OPA-15406Latest Information Update: 23 Aug 2024
At a glance
- Originator Otsuka Pharmaceutical Development & Commercialization
- Developer Acrotech Biopharma; Medimetriks Pharmaceuticals; Otsuka Beijing Research Institute; Otsuka Pharmaceutical Development & Commercialization
- Class Benzamides; Nonsteroidal anti-inflammatories; Oxazoles; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis
Most Recent Events
- 31 Jul 2024 Acrotech Biopharma completed phase III clinical trials in Atopic dermatitis (In adolescents, In children, In adults, In the elderly) in USA (Topical) (NCT05571943)
- 29 Nov 2023 Otsuka Pharmaceutical completes a phase-III clinical trials in Atopic dermatitis (In infants) in Japan (Topical) (NCT05372653)
- 27 Oct 2023 Acrotech Biopharma completes a phase III trial in Atopic dermatitis (In adolescents, In children, In adults, In the elderly) in USA (Topical) (NCT05608343)